CBCarlo Buzio

Carlo Buzio

*This is an algorithmically generated author record based on publicly available information.

Carlo Buzio has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 1 January 2007
      • Vol. 78  (1) , 51-9

    HCV-related cryoglobulinemic glomerulonephritis: implications of antiviral and immunosuppressive therapies.

    by Giovanni Garini, Landino Allegri, Francesco Iannuzzella, Augusto Vaglio, Carlo Buzio

    The most frequent renal involvement in patients with chronic hepatitis C virus (HCV) infection is cryoglobulinemic glomerulonephritis, with type I membranoproliferative glomerulonephritis (MPGN) being the predominant histological pattern. The pathogenesis of HCV-related cryoglobulinemic MPGN is unknown, but the glomerular damage may be due to the deposition of immune complexes of HCV, IgG, and IgM rheumatoid factors. Clinically, cryoglobulinemic MPGN may range from isolated proteinuria to overt nephritic or nephrotic syndrome, with variable progression to chronic renal insufficiency. The management of cryoglobulinemic MPGN is difficult; the eradication of HCV by means of antiviral therapy (peginterferon plus ribavirin) leads to clinical remission in a proportion of patients, but severe renal disease may be resistant to antiviral therapy. In such cases, corticosteroids and immunosuppressive agents have been used to decrease cryoglobulin production and improve the vasculitic manifestations, but long-lasting remission of the renal disease is uncommon. Here we describe four patients with HCV-related cryoglobulinemic MPGN and the strategies used for their management. The principal message provided by these illustrative cases is that antiviral therapy alone can be the first-line treatment for patients with mild-to-moderate kidney involvement, whereas a short-term course of corticosteroids and cytotoxic agents followed by antiviral therapy may be a reasonable therapeutic strategy for patients with severe/active renal disease.


  • Open Access

    Tuberculosis as a Trigger of Retroperitoneal Fibrosis

    by Paolo Greco, Augusto Vaglio, Domenico Corradi, Rocco Cobelli, Maurizio Zompatori, Carlo Buzio

    Potential conflicts of interest. All authors: no conflicts.


  • 18F‐fluorodeoxyglucose positron emission tomography in the diagnosis and followup of idiopathic retroperitoneal fibrosis

    by Augusto Vaglio, Annibale Versari, Alessandro Fraternali, Francesco Ferrozzi, Carlo Salvarani, Carlo Buzio


  • Low doses of subcutaneous interleukin-2 plus interferon-α do not induce thyroid function alterations in advanced renal cell carcinoma patients

    by Andrea Sartore-Bianchi, Alessandra Soriani, Raffaella Mattioni, Augusto Vaglio, Carlo Buzio, Camillo Porta

    The incidence of thyroid function changes among renal cell carcinoma (RCC) patients treated with high-dose IL-2 plus IFN-α ranges from 9 to 59%, independently of the administration route (i.v. or s.c.) of IL-2. Although several studies demonstrated a correlation between high-dose IL-2/IFN-α regimens and autoimmune thyroid disease, only very limited data are available when low doses of IL-2 plus IFN-α are used. We prospectively studied thyroid function in 52 patients with metastatic RCC undergoing immunotherapy with low-dose IL-2 + IFN-α. All patients received treatment cycles consisting of both s.c. IL-2 and i.m. IFN-α for 4 consecutive weeks; cycles were repeated at 4-month intervals in all patients, irrespectively of their response. Thyroid stimulating hormone (TSH), 3,3',5-triiodo-L-thyronine (T3), thyroxine (T4), human anti-thyroglobulin antibodies (hTg-Ab) and human anti-thyroid peroxidase antibodies (hTPO-Ab) were assayed in all patients before and after each of the first 3 cycles. None of the patients showed clinical signs of dysthyroidism, nor required replacement or suppressive treatment on thyroid function; specifically, no statistically significant differences were found when the median pre- and post-treatment TSH, T3, T4, hTg-Ab and hTPO-Ab levels of each cycle were compared. The median TSH values after the 3 cycles were, respectively, 1.06 [Inter Quartile Range (IQR) 0.58-1.51], 1.21 (IQR 0.58-1.51) and 1.05 µU/ml (IQR 0.67-1.73). As for thyroid hormones, median values after each of the 3 cycles were: 1.38 (IQR 1.19-1.50), 1.46 (IQR 1.17-1.66) and 1.36 (IQR 1.16-1.46) ng/ml for T3, and 8.74 (IQR 7.26-9.45), 8.67 (IQR 7.12-9.18) and 8.40 (IQR 7.12-9.33) µg/dl for T4. These data show that a regimen of low-dose IL-2 plus IFN-α does not seem to affect thyroid function, neither inducing signs or symptoms of dysthyroidism, nor by causing major biochemical changes in TSH and thyroid hormone levels, or an increase in thyroid-specific auto-antibodies.


    • 1 August 2004
      • Vol. 75  (2) , 126-30

    "Late" regressions of metastases from renal cancer after a period of disease progression continuing the same intermittent low dose immunotherapy regimen.

    by Roberto Giacosa, Rosaria Santi, Augusto Vaglio, Laura Pavone, Francesco Ferrozzi, Rodolfo Passalacqua, Carlo Buzio

    We here describe two patients with metastatic renal cell cancer (mRCC) treated with immunotherapy in whom the metastases completely regressed after a period of progressive disease. The treatment schedule was based on repeated cycles of low-dose recombinant interleukin-2 and recombinant interferon-alpha, and was never changed during the course of the disease. The first patient received immunotherapy because of multiple bilateral lung metastases. Progressive disease, with mediastinal lymph node involvement and an increased number of lung metastases, was observed after 30 months of regularly repeated therapy; complete regression was achieved after 60 months of immunotherapy (after 16 immunotherapy cycles). The second patient began immunotherapy because of three small lung metastases. Disease progression was observed after three cycles, but complete regression was obtained about 16 months after the start of immunotherapy (after 5 immunotherapy cycles). Long-term low-dose immunotherapy may bring about an effective anti-tumour response even late in the course of the disease and after an initial disease progression.

    • 1 December 2003
      • Vol. 94  (12) , 573-81

    [Churg-Strauss syndrome].

    by Giovanni Garini, Domenico Corradi, Augusto Vaglio, Carlo Buzio

    Churg-Strauss syndrome (CSS) is a rare systemic vasculitis occurring in patients with a history of asthma or allergy and eosinophilia. Although lungs, skin, and peripheral nervous system are the most common sites of involvement, many other organs, including heart, kidneys, and gastrointestinal tract, can be affected. CSS is an eosinophil-mediated disease, but its pathophysiology is not fully known. There are no specific laboratory tests for CSS. The main laboratory characteristics are peripheral blood eosinophilia, elevated serum IgE levels, and the presence of an inflammatory syndrome. Antineutrophil cytoplasmic antibodies directed against myeloperoxidase are positive in approximately one-half of patients. The diagnosis of CSS rests on the association of the clinical features of the disease with its histologic hallmarks. The biopsy of affected tissues may show a spectrum of histologic changes, including leukocytoclastic or necrotizing vasculitis, eosinophilic tissue infiltration, vascular and extravascular granulomas. The involved vessels are small arteries, veins, arterioles, venules, and capillaries. Corticosteroids, sometimes in combination with a cytotoxic agent, such as cyclophosphamide, are the most effective treatment of CSS. Intravenous immunoglobulins or interferon-alpha may be useful for patients refractory to conventional treatment.


  • ANCA‐positive periaortic vasculitis: does it fall within the spectrum of vasculitis?

    by A. Vaglio, L. Manenti, L. Allegri, F. Ferrozzi, D. Corradi, C. Buzio

    Vaglio A, Manenti L, Allegri L, Ferrozzi F, Corradi D, Buzio C (University of Parma, Parma, Italy). ANCA‐positive periaortic vasculitis: does it fall within the spectrum of vasculitis? (Case Report). J Intern Med 2002; 251: 268–271.Retroperitoneal fibrosis (RPF) is a disease of unknown aetiology that has sometimes been reported in association with connective tissue disorders and systemic vasculitis. We report here two cases of antineutrophil cytoplasmic antibody (ANCA)‐positive RPF showing clinical evidence of rapidly progressive glomerulonephritis. Although treatment with prednisone and cyclophosphamide led to a remission of RPF in both cases, renal function was restored in only one patient and the other progressed to chronic renal failure. The paper reviews the literature concerning ANCA‐positive RPF and discusses the relationship between ANCA‐positive vasculitis and RPF.